Pitavastatin Shows Promise as New Therapy for Triple‑Negative Breast Cancer

Here’s a list of the references, formatted for easier citation:

1. Cleveland Clinic. Statins. https://my.clevelandclinic.org/health/treatments/22282-statins.Accessed January 9, 2026.
2. Drugbank. Pitavastatin. https://go.drugbank.com/drugs/DB08860. Accessed January 9, 2026.
3. O’Grady S, Crown J, Duffy MJ. Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells. Med Oncol. 2022;39(10):142. published July 14, 2022. doi:10.1007/s12032-022-01733-9
4. McKechnie T, Brown Z, Lovrics O, et al. Concurrent Use of Statins in Patients undergoing Curative intent Treatment for Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis. Clin Breast Cancer. 2024;24(3):e103-e115. doi:10.1016/j.clbc.2023.12.001
5. Hillis AL, Martin TD, Manchester HE, et al.Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer. Cancer Res. 2024;84(19):3250-3266. doi:10.1158/0008-5472.CAN-24-0970
6. Tang WJ, Xu D, Liang MX, et al. Pitavastatin induces autophagy-dependent ferroptosis in MDA-MB-231 cells via the mevalonate pathway. Heliyon. 2024;10(5):e27084. doi:10.1016/j.heliyon.2024.e27084
7. Drug target Review. Pitavastatin identified as potential treatment for triple-negative breast cancer. https://www.drugtargetreview.com/news/192057/pitavastatin-identified-as-potential-treatment-for-triple-negative-breast-cancer/. Published January 8,2026. Accessed January 9, 2026.